Compounds of the formula:
are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.
Anti-allergic-3-carboxy-isocoumarin compositions and methods of use
申请人:Beecham Group Limited
公开号:US03975535A1
公开(公告)日:1976-08-17
3-Carboxyisocoumarins, 2-thiaisocoumarins and related isocarbostyrils are useful anti-allergic agents. Several of these compounds are novel, and a process for their preparation is provided.
Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of
申请人:Beecham Group Limited
公开号:US04036964A1
公开(公告)日:1977-07-19
3-Carboxyisocoumarins, 2-thiaisocoumarins and related isocarbostyrils are useful anti-allergic agents. Several of these compounds are novel, and a process for their preparation is provided.
A H4SiW12O40-catalyzed three-component tandem reaction for the synthesis of 3,3-disubstituted isoindolinones
作者:Yufeng Liu、Guodong Zeng、Yutao Cheng、Lei Chen、Yunhai Liu、Yongge Wei、Guoping Yang
DOI:10.1016/j.cclet.2023.108480
日期:2024.1
A H4SiW12O40-catalyzed three-component tandemreaction of 2-acylbenzoic acids, primary amines and phosphine oxides to form 3,3-disubstituted isoindolinones was developed. By employing H4SiW12O40 as the catalyst and dimethyl carbonate (DMC) as the solvent, a diverse range of 2-acylbenzoic acid derivatives and primary amines worked well to give the C3-phosphinoyl-functionalized 3,3-disubstituted isoindolinones
开发了AH 4 SiW 12 O 40催化的2-酰基苯甲酸、伯胺和氧化膦的三组分串联反应以形成3,3-二取代异吲哚啉酮。通过使用 H 4 SiW 12 O 40作为催化剂和碳酸二甲酯 (DMC) 作为溶剂,各种 2-酰基苯甲酸衍生物和伯胺都能很好地产生 C3-膦酰基官能化的 3,3-二取代异吲哚啉酮收率范围为61%-87%。这种转化的优点包括绿色催化剂和溶剂、可用的起始原料、广泛的底物范围、高效率和操作简单,水作为唯一的副产物。该策略实现了高效、绿色的分子片段组装来获取异吲哚啉酮,这将为以绿色方式合成潜在的生物活性分子提供机会。
N-Alkanoylphenylalanine derivatives
申请人:F.HOFFMANN-LA ROCHE AG
公开号:EP1403247A1
公开(公告)日:2004-03-31
Compounds of the formula:
as well as their salts and esters are disclosed wherein X, X', Z, and Y are as described in the specification and which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.